ESC Premium Access

The SGLT2 inhibitor era: what more can we expect?

Topic: Diabetes and the Heart
Sponsored by The Boehringer Ingelheim, Eli Lilly and Company Alliance

Congress Presentation

About the speaker

Professor Stefan Anker

Charite University Hospital, Berlin (Germany)
171 presentations
10 followers

4 more presentations in this session

Welcome and introduction

Speaker: Professor T. Luscher (London, GB)

Thumbnail

The role of SGLT2 inhibitors in CV risk reduction in patients with type 2 diabetes

Speaker: Professor S. Kaul (Los Angeles, US)

Thumbnail

Taking the initiative: the cardiologist´s perspective

Speaker: Professor N. Marx (Aachen, DE)

Thumbnail

Audience questions and answers, summary and close

Speaker: Professor T. Luscher (London, GB)

Thumbnail

Access the full session

SGLT2 inhibitors in clinical cardiology: modern-day cardiovascular management in patients with type 2 diabetes

Speakers: Professor S. Anker, Professor T. Luscher, Professor S. Kaul, Professor N. Marx, Professor T. Luscher
Thumbnail

About the event

Image

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations